Staar Surgical 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third quarter 2026 net sales were $83.4 million, down 12% year over year; excluding $25.9 million of China deferred sales in the third quarter 2025, sales increased 21% from $68.8 million.
- China net sales were $39.3 million, up 31% from $29.9 million excluding China deferred sales; all China net sales growth came from higher average selling prices, driven by the mix shift to B5 and Toric ICLs.
- Distributor unit shipments in China grew 12.4% through the first 9 months, while distributor inventory declined over the past 4 quarters to below the 6-month target.
- Outside China, net sales increased 13% to $44.1 million; Asia Pacific excluding China grew 4%, EMEA grew 31% (51% excluding the Middle East), and the Americas grew 14%.
- Third quarter gross margin was 70.9%, compared with 82.2% a year earlier; excluding the China deferred sales effect, prior-year gross margin would have been 75.5%.
- Third quarter operating expenses were $53.7 million, compared with $59.4 million including $6 million of prior-year restructuring and merger-related costs; excluding those costs, operating expenses were approximately flat year over year.
- Third quarter operating income was $5.5 million; GAAP net income was $5.6 million, or $0.11 per diluted share; adjusted EBITDA was $14.4 million, or $0.28 per diluted share.
- Cash, cash equivalents, and investments available for sale totaled $206.4 million as of October 2nd, 2026, compared with $181.5 million at the end of the second quarter; STAAR had no outstanding debt.
- STAAR reported record net sales through the first 9 months, strong adjusted EBITDA and free cash flow, and a debt-free balance sheet.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please note, this event is being recorded. I would now like to turn the call over to Connie Johnson, Director of Investor Relations.
Please go ahead. Thank you, operator.
Good afternoon, and thank you for joining us. On the call today are Warren Foust, President and Chief Executive Officer of STAAR Surgical, and Deborah Andrews, Executive Vice President and Chief Financial Officer of STAAR Surgical. Earlier today, we reported our third quarter 2026 results. We posted our results release and shareholder letter to our investor website at investors.staar.com. Today's call is scheduled for one hour and will include Q&A for publishing analysts. We also invite webcast participants to send questions to ir@staar.com. Before we get started, during today's discussion, we will be making forward-looking statements. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Please read the disclosures in today's release and our SEC filings.
Except as required by law, STAAR assumes no obligation to update these statements to reflect future events or actual outcomes. We will also reference certain non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA per diluted share, free cash flow, and results excluding the China deferred sales. Please refer to today's release for additional information and applicable reconciliations to the most directly comparable GAAP measures. Unless otherwise specified, all comparisons will be year-over-year. Finally, we intend to use our investor website to disclose material non-public information and comply with Regulation FD. Please monitor that website along with our press releases, SEC filings, and public calls and webcasts. With that, I would like to turn the presentation over to Warren.
Warren? Thank you, Connie. Good afternoon, everyone, and thank you for joining us.
At the start of the year, we set three goals: revenue growth, profit expansion, and innovation acceleration. Through the first nine months, we've made progress on all three. Year-to-date, we delivered record revenue, achieved strong profitability, and took important steps toward bringing our next generation of products to patients. Our strong cash flow and debt-free balance sheet give us flexibility to keep investing in that future. I want to thank our teams in China and Japan, our two largest markets, as well as all of our dedicated employees in Switzerland and the United States, and all around the world.
This year, they implemented a new ERP system, completed the move of China-bound ICL manufacturing to Switzerland, ramped production to support the EVO+ launch in China, and began the clinical trial process for two new lenses, all while continuing to serve surgeons and patients. That is a lot of change, and they have delivered and continue to do so, strengthening how we operate and laying further groundwork for future growth. Let's talk about where we stand. Let me start with revenue growth, which is being driven by an ongoing shift from lasers to lenses. With China being our largest market, let's go right there and spend a little time. In the third quarter, excluding the $25.9 million recognized in the third quarter 2025, revenue grew 31%.
Distributor unit shipments in the China market grew 12.4% through the first nine months, a step up from mid-single-digit growth in 2025, outpacing the broader Chinese refractive market. We are encouraged that hundreds of mid-tier hospitals have begun to close the gap with our largest and longest-established centers, which continue to set the benchmark for ICL productivity and have recently publicly cited EVO+ as a driver of their growth. Recent commentary from Aier provides one useful perspective. In reporting on its third quarter performance, Aier cited rising penetration of premium refractive procedures, including EVO+, as supporting a better procedure mix. That is consistent with what we are seeing in EVO+ adoption across China. Mix is helping us as well.
Adoption of EVO+ and toric lenses is raising our average selling prices, and because we were not yet able to fully meet the demand for lenses in the third quarter, all of our China net sales growth came from higher average selling prices. Our focus on ensuring proper inventory levels continues to pay off as well. In fact, distributor inventory has declined over the past four quarters to below our six-month target, while in-market unit volume shipments have grown. Alongside our inability to fully meet third-quarter lens demand, this reinforces our focus on expanding manufacturing capacity. As available supply improves, we expect our shipments to our distributors to reflect underlying demand more closely. We are quite pleased with our progress in China. Globally, we delivered record revenue through the first nine months. Turning back to regional performance, APAC, excluding China, grew 4%.
Revenue growth in India, Taiwan, and other markets was partly offset by a slight decline in Japan, primarily due to currency, and South Korea, primarily caused by overall market weakness. In EMEA, we grew 31%, or 51% excluding the Middle East. Our growth was driven by strong double-digit growth in Spain, Germany, and the U.K. We round out our global performance with the Americas, which put up 14% growth. Growth in the Americas was led by the U.S., where we posted our third consecutive quarter of greater than $6 million in sales. In the U.S., the opportunity is not only about gaining share within the existing refractive surgery market, it is about helping practices reach appropriate patients who have remained on the sidelines. Refractive Surgery Council data indicate that U.S. laser vision correction procedures have declined 5.8% in 2026 versus 2025, while our sales grew double digits.
We believe the ongoing structural shift of the refractive surgery market from lasers to lenses is an important long-term growth driver. In September, we published our market report, The Future of Refractive Surgery, which shows the ongoing shift from laser-based to lens-based vision correction in multiple markets. Our consumer research shows that patients want freedom from glasses and contacts, and that they place a high value on safety, choice, and reversibility. Our job is to help practices turn that interest into treatment. On profit, we continue making progress, and there is more work to do. For the first three quarters, we have delivered record revenue, strong adjusted EBITDA, and free cash flow, and we remain debt-free. Excluding the impact of the China deferred sales on the prior year comparison, we improved from an adjusted net loss in last year's third quarter to GAAP net income this quarter.
Gross margin in the third quarter was affected by several temporary factors, including the ERP implementation, freight, tariffs, and inventory provisions. Looking ahead, we expect fourth quarter gross margin to be above the third quarter, and we expect gross margin to continue to improve in 2027 as unit costs improve with both our U.S. and our Swiss production facilities running at full capacity. Our operational priorities are clear: improve product availability, increase manufacturing yields, and allocate capital where it offers the best return on shareholder investment. In September, our board authorized a $50 million share repurchase program, reflecting its confidence in the business and its belief that STAAR shares are undervalued. We will continue to take a disciplined, returns-focused approach to capital allocation to maximize shareholder value creation over time. That brings me to our third goal: innovation acceleration. We are focused on innovating in three key areas.
Of course, product innovation, but also commercial innovation, as well as operational innovation. When we talk about product innovation, we're focused on the future of vision. Collamer is at the heart of what makes EVO different. With more than 30 years of clinical evidence, over 100,000 eyes studied, and more than 4 million lenses distributed worldwide, we believe that EVO ICL stands as the most clinically validated phakic IOL in the world, giving us a strong foundation for expanding beyond our core offering. Ben Park, our recently appointed Chief Technology Officer, is leading our R&D team's work across a variety of therapeutic areas. Ben joined us a few months ago and is already making an impact. I'm excited about how his engineering, material science, and commercialization experience will help us harness Collamer's advantage to develop new products. We are approaching an important milestone.
First-in-human trials for two Collamer-based presbyopia products are expected to begin patient enrollment in the next few months, subject to the receipt of the remaining required regulatory authorizations. These studies are a tangible step from pipeline to patient. Our ambition is to build toward a meaningful product launch in a critical market every 18 to 24 months. It will take time to build that reality, but we are already on that journey, and I'm excited by the potential. Our commercial innovation strategy is clear: make EVO ICL a primary option for patients who want freedom from glasses and contacts. That means deeper adoption with surgeons already choosing EVO, expanding into lower diopters, and reaching new patients who are searching for freedom from glasses or contact lenses. To lead that effort, David Bailey, a former STAAR CEO, returned in September as Chief Commercial Officer.
David built much of what our commercial engine is today, and he has a clear mandate to drive deeper surgeon adoption of EVO. That means better education, stronger evidence programs, smarter use of data, and more targeted patient awareness, market by market and surgeon by surgeon. We also welcomed Andrew Pilon as Vice President of Business Development to expand strategic partnerships and our global footprint. Earlier this week, we appointed Pascal Aeschlimann as Vice President of Asia Pacific. Pascal helped lead our expansion across Asia and the Middle East during his earlier tenure with STAAR. Recent label expansions raised U.S. eligibility to age 60, adding approximately 8 million potentially eligible patients, and lowered Brazil's minimum prescription to minus 0.5 diopters, adding an estimated 26 million potential patients. Our opportunity is to help appropriate newly eligible patients access treatment. Finally, operational innovation is about delivering with excellence.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
